Search Results - "Guttman, E"

Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2) by Wollenberg, A., Blauvelt, A., Guttman‐Yassky, E., Worm, M., Lynde, C., Lacour, J.‐P., Spelman, L., Katoh, N., Saeki, H., Poulin, Y., Lesiak, A., Kircik, L., Cho, S.H., Herranz, P., Cork, M.J., Peris, K., Steffensen, L.A., Bang, B., Kuznetsova, A., Jensen, T.N., Østerdal, M.L., Simpson, E.L.

“…Summary Background Tralokinumab, a fully human monoclonal antibody, specifically neutralizes interleukin‐13, a key cytokine driving peripheral inflammation in…”
Get full text

Baricitinib in patients with moderate‐to‐severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials by Simpson, E.L., Lacour, J.‐P., Spelman, L., Galimberti, R., Eichenfield, L.F., Bissonnette, R., King, B.A., Thyssen, J.P., Silverberg, J.I., Bieber, T., Kabashima, K., Tsunemi, Y., Costanzo, A., Guttman‐Yassky, E., Beck, L.A., Janes, J.M., DeLozier, A.M., Gamalo, M., Brinker, D.R., Cardillo, T., Nunes, F.P., Paller, A.S., Wollenberg, A., Reich, K.

“…Summary Background Baricitinib, an oral selective Janus kinase 1 and 2 inhibitor, effectively reduced atopic dermatitis (AD) severity in a phase II study with…”
Get full text

Conjunctivitis in dupilumab clinical trials by Akinlade, B., Guttman‐Yassky, E., Bruin‐Weller, M., Simpson, E.L., Blauvelt, A., Cork, M.J., Prens, E., Asbell, P., Akpek, E., Corren, J., Bachert, C., Hirano, I., Weyne, J., Korotzer, A., Chen, Z., Hultsch, T., Zhu, X., Davis, J.D., Mannent, L., Hamilton, J.D., Teper, A., Staudinger, H., Rizova, E., Pirozzi, G., Graham, N.M.H., Shumel, B., Ardeleanu, M., Wollenberg, A.

“…Summary Background Dupilumab blocks the shared receptor component for interleukin (IL)‐4 and IL‐13. It is approved in the U.S.A. for patients aged ≥ 12 years…”
Get full text

Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement by Drucker, A.M., Eyerich, K., de Bruin‐Weller, M.S., Thyssen, J.P., Spuls, P.I., Irvine, A.D., Girolomoni, G., Dhar, S., Flohr, C., Murrell, D.F., Paller, A.S., Guttman‐Yassky, E.

“…Summary Background Guidelines discourage the use of systemic corticosteroids for atopic dermatitis (AD), but their use remains widespread. Objectives To reach…”
Get full text

The oral Janus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate‐to‐severe atopic dermatitis: results from a randomized double‐blind placebo‐controlled study by Bissonnette, R., Maari, C., Forman, S., Bhatia, N., Lee, M., Fowler, J., Tyring, S., Pariser, D., Sofen, H., Dhawan, S., Zook, M., Zammit, D.J., Usansky, H., Denis, L., Rao, N., Song, T., Pavel, A.B., Guttman‐Yassky, E.

“…Summary Background ASN002 is an oral dual inhibitor of Janus kinase and spleen tyrosine kinase, which are involved in the pathogenesis of atopic dermatitis…”
Get full text

Pioneering global best practices in atopic dermatitis: results from the atopic dermatitis quality of care initiative by Guttman‐Yassky, E., Nosbaum, A., Simpson, E., Weidinger, S.

“…Summary Background Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by unrelenting pruritus and recurrent eczematous lesions. It…”
Get full text

Alopecia areata is characterized by expansion of circulating Th2/Tc2/Th22, within the skin‐homing and systemic T‐cell populations by Czarnowicki, T., He, H. Y., Wen, H.‐C., Hashim, P. W., Nia, J. K., Malik, K., Estrada, Y., Kimmel, G. W., Taliercio, M., Krueger, J. G., Guttman‐Yassky, E.

“…Background Characterizing blood profile of alopecia areata (AA) is important not only for treatment advancements, but also for possibly identifying peripheral…”
Get full text

Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways by Nograles, K.E., Zaba, L.C., Guttman-Yassky, E., Fuentes-Duculan, J., Suárez-Fariñas, M., Cardinale, I., Khatcherian, A., Gonzalez, J., Pierson, K.C., White, T.R., Pensabene, C., Coats, I., Novitskaya, I., Lowes, M.A., Krueger, J.G.

“…Summary Background  Psoriasis vulgaris is an inflammatory skin disease mediated by Th1 and Th17 cytokines, yet the relative contribution of interferon (IFN)‐γ,…”
Get full text

Frontal fibrosing alopecia shows robust T helper 1 and Janus kinase 3 skewing by Del Duca, E., Ruano Ruiz, J., Pavel, A.B., Sanyal, R.D., Song, T., Gay‐Mimbrera, J., Zhang, N., Estrada, Y.D., Peng, X., Renert‐Yuval, Y., Phelps, R.G., Paus, R., Krueger, J.G., Guttman‐Yassky, E.

“…Summary Background Frontal fibrosing alopecia (FFA) is a scarring alopecia with unclear pathogenesis and a progressive course. The disease has a major impact…”
Get full text

Keloid lesions show increased IL‐4/IL‐13 signaling and respond to Th2‐targeting dupilumab therapy by Diaz, A., Tan, K., He, H., Xu, H., Cueto, I., Pavel, A.B., Krueger, J.G., Guttman‐Yassky, E.

Get full text

Nonlesional atopic dermatitis skin shares similar T‐cell clones with lesional tissues by Brunner, P. M., Emerson, R. O., Tipton, C., Garcet, S., Khattri, S., Coats, I., Krueger, J. G., Guttman‐Yassky, E.

“…Background Atopic dermatitis (AD) is characterized by robust immune activation. Various T‐cell subsets, including Th2/Th22 cells, are increased in lesional and…”
Get full text

Chronic hand eczema understanding has ramifications on clinical management by Thyssen, J.P., Silverberg, J.I., Guttman‐Yassky, E.

Get full text

Circulating CLA+ T cells in atopic dermatitis and their possible role as peripheral biomarkers by Czarnowicki, T., Santamaria‐Babí, L. F., Guttman‐Yassky, E.

“…Cutaneous lymphocyte‐associated antigen (CLA+) T cells are specialized for skin homing and represent the main T‐cell population in atopic dermatitis (AD)…”
Get full text

Identification of unique proteomic signatures in allergic and non‐allergic skin disease by Wang, J., Suárez‐Fariñas, M., Estrada, Y., Parker, M. L., Greenlees, L., Stephens, G., Krueger, J., Guttman‐Yassky, E., Howell, M. D.

“…Summary Background Atopic dermatitis (AD), psoriasis (PS), and contact dermatitis (CD) are common skin diseases, characterized by barrier disruption and…”
Get full text

Priority research questions in atopic dermatitis: an International Eczema Council eDelphi consensus by Abuabara, K., Nicholls, S.G., Langan, S.M., Guttman‐Yassky, E., Reynolds, N.J., Paller, A.S., Brown, S.J.

Get full text

CARD14 alterations in Tunisian patients with psoriasis and further characterization in European cohorts by Ammar, M., Jordan, C.T., Cao, L., Lim, E., Bouchlaka Souissi, C., Jrad, A., Omrane, I., Kouidhi, S., Zaraa, I., Anbunathan, H., Mokni, M., Doss, N., Guttman-Yassky, E., El Gaaied, A. B., Menter, A., Bowcock, A.M.

“…Summary Background Rare highly penetrant gain‐of‐function mutations in caspase recruitment domain family, member 14 (CARD14) can lead to psoriasis, a chronic…”
Get full text

Generation and Characterization of the Western Regional Research Center Brachypodium T-DNA Insertional Mutant Collection by Bragg, Jennifer N, Wu, Jiajie, Gordon, Sean P, Guttman, Mara E, Thilmony, Roger, Lazo, Gerard R, Gu, Yong Q, Vogel, John P, Hazen, Samuel P

“…The model grass Brachypodium distachyon (Brachypodium) is an excellent system for studying the basic biology underlying traits relevant to the use of grasses…”
Get full text

Incident alopecia areata and vitiligo in adult women with atopic dermatitis: Nurses’ Health Study 2 by Drucker, A. M., Thompson, J. M., Li, W.‐Q., Cho, E., Li, T., Guttman‐Yassky, E., Qureshi, A. A.

“…We aimed to determine the risk of alopecia areata (AA) and vitiligo associated with atopic dermatitis (AD) in a large cohort of US women, the Nurses’ Health…”
Get full text

Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy – international eczema council survey and opinion by Thyssen, J.P., Bruin‐Weller, M.S., Paller, A.S., Leshem, Y.A., Vestergaard, C., Deleuran, M., Drucker, A.M., Foelster‐Holst, R., Traidl‐Hoffmann, C., Eyerich, K., Taieb, A., Su, J.C., Bieber, T., Cork, M.J., Eichenfield, L.F., Guttman‐Yassky, E., Wollenberg, A.

“…Background Conjunctivitis is common in patients with atopic dermatitis (AD) in general and a commonly reported adverse event in AD clinical trials with…”
Get full text

Atopic dermatitis among children and adolescents in the Arctic region – a systematic review and meta‐analysis by Andersson, A.M., Halling, A.S., Loft, N., Skov, L., Koch, A., Guttman‐Yassky, E., Thyssen, J.P.

“…The prevalence of atopic dermatitis (AD) varies across the globe, and the clinical phenotype with racial background and ethnicity. AD in the Arctic region has…”
Get full text